Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Immunotherapy in Triple Negative Breast Cancer
share announcement

Immunotherapy in Triple Negative Breast Cancer

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: closed (28 February 2023) | Viewed by 7703

Special Issue Editor

Dr. Yuanliang Yan

E-Mail Website
Guest Editor
Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China
Interests: pharmaceutics; pharmacology; cancer therapy; translating mechanistic insights gained for new therapeutic modalities

Special Issue Information

Dear Colleagues, 

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer, leading to poor prognosis and therapeutic response. Today, immunotherapy, such as immune checkpoint inhibitors (ICIs) and cell vaccine, is increasingly being used to treat TNBC patients. The biological function of immunotherapy in TNBC has resulted in durable clinical response and improved clinical outcomes. These findings have helped us to understand the importance of immune-response-based strategies for TNBC treatment. The aim of this Special Issue in the Journal of Personalized Medicine (JPM) is to highlight the current state of the report and showcase some of the latest findings in the field of immune-response-based strategies for TNBC patients. Manuscripts based on basic science, clinical, and population-based approaches are especially welcome.

Dr. Yuanliang Yan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • triple-negative breast cancer
  • immunotherapy
  • immune checkpoint inhibitors
  • cell vaccine
  • immune response
  • immune cell homeostasis

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 3854 KiB  
Article
A Comprehensive Analysis of Programmed Cell Death-Associated Genes for Tumor Microenvironment Evaluation Promotes Precise Immunotherapy in Patients with Lung Adenocarcinoma
by Yunxi Huang, Wenhao Ouyang, Zehua Wang, Hong Huang, Qiyun Ou, Ruichong Lin, Yunfang Yu and Herui Yao
J. Pers. Med. 2023, 13(3), 476; https://doi.org/10.3390/jpm13030476 - 6 Mar 2023
Cited by 1 | Viewed by 1625
Abstract
Immune checkpoint inhibitors (ICIs) represent a new hot spot in tumor therapy. Programmed cell death has an important role in the prognosis. We explore a programmed cell death gene prognostic model associated with survival and immunotherapy prediction via computational algorithms. Patient details were [...] Read more.
Immune checkpoint inhibitors (ICIs) represent a new hot spot in tumor therapy. Programmed cell death has an important role in the prognosis. We explore a programmed cell death gene prognostic model associated with survival and immunotherapy prediction via computational algorithms. Patient details were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus databases. We used LASSO algorithm and multiple-cox regression to establish a programmed cell death-associated gene prognostic model. Further, we explored whether this model could evaluate the sensitivity of patients to anti-PD-1/PD-L1. In total, 1342 patients were included. We constructed a programmed cell death model in TCGA cohorts, and the overall survival (OS) was significantly different between the high- and low-risk score groups (HR 2.70; 95% CI 1.94–3.75; p < 0.0001; 3-year OS AUC 0.71). Specifically, this model was associated with immunotherapy progression-free survival benefit in the validation cohort (HR 2.42; 95% CI 1.59–3.68; p = 0.015; 12-month AUC 0.87). We suggest that the programmed cell death model could provide guidance for immunotherapy in LUAD patients. Full article
(This article belongs to the Special Issue Immunotherapy in Triple Negative Breast Cancer)
►▼ Show Figures

Figure 1

16 pages, 8830 KiB  
Article
Comprehensive Analysis of Necroptosis-Related Genes as Prognostic Factors and Immunological Biomarkers in Breast Cancer
by Yingkun Xu, Qiulin Wu, Zhenrong Tang, Zhaofu Tan, Dongyao Pu, Wenhao Tan, Wenjie Zhang and Shengchun Liu
J. Pers. Med. 2023, 13(1), 44; https://doi.org/10.3390/jpm13010044 - 26 Dec 2022
Cited by 2 | Viewed by 1526
Abstract
Breast cancer (BC) is a lethal malignancy with a poor prognosis. Necroptosis is critical in the progression of cancer. However, the expression of genes involved in necroptosis in BC and their association with prognosis remain unclear. We investigated the predictive potential of necroptosis-related [...] Read more.
Breast cancer (BC) is a lethal malignancy with a poor prognosis. Necroptosis is critical in the progression of cancer. However, the expression of genes involved in necroptosis in BC and their association with prognosis remain unclear. We investigated the predictive potential of necroptosis-related genes in BC samples from the TCGA dataset. We used LASSO regression to build a risk model consisting of twelve necroptosis-related genes in BC. Using the necroptosis-related risk model, we were able to successfully classify BC patients into high- and low-risk groups with significant prognostic differences (p = 4.872 × 10 −7). Additionally, we developed a matched nomogram predicting 5, 7, and 10-year overall survival in BC patients based on this necroptosis-related risk model. Our next step was to perform multiple GSEA analyses to explore the biological pathways through which these necroptosis-related risk genes influence cancer progression. For these twelve risk model genes, we analyzed CNV, SNV, OS, methylation, immune cell infiltration, and drug sensitivity in pan-cancer. In addition, immunohistochemical data from the THPA database were used to validate the protein expression of these risk model genes in BC. Taken together, we believe that necroptosis-related genes are considered potential therapeutic targets in BC and should be further investigated. Full article
(This article belongs to the Special Issue Immunotherapy in Triple Negative Breast Cancer)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 599 KiB  
Review
Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
by Tinglin Yang, Wenhui Li, Tao Huang and Jun Zhou
J. Pers. Med. 2023, 13(3), 526; https://doi.org/10.3390/jpm13030526 - 15 Mar 2023
Cited by 7 | Viewed by 4096
Abstract
The advent of immunotherapy, especially immune checkpoint inhibitors (ICIs), has revolutionized antitumor therapy. Programmed cell death receptor 1 (PD-1) and programmed cell death ligand 1 (PD-L1) are among the most promising targets for encouraging the immune system to eliminate cancer cells. PD-1/PD-L1 have [...] Read more.
The advent of immunotherapy, especially immune checkpoint inhibitors (ICIs), has revolutionized antitumor therapy. Programmed cell death receptor 1 (PD-1) and programmed cell death ligand 1 (PD-L1) are among the most promising targets for encouraging the immune system to eliminate cancer cells. PD-1/PD-L1 have made clinical remission for numerous solid tumors, including metastatic triple-negative breast cancer (TNBC). In recent years, integrating PD-1/PD-L1 inhibitors into existing treatments in early-stage TNBC has attracted wide attention. Herein, we summarize the clinical benefit of PD-1/PD-L1 inhibitors plus neoadjuvant chemotherapy, adjuvant chemotherapy, and targeted therapy in early-stage TNBC. Possible immunotherapy biomarkers, immune-related adverse events (irAEs), and the key challenges faced in TNBC anti-PD-1/PD-L1 therapy are also concluded. Numerous studies on immunotherapy are ongoing, and PD-1/PD-L1 inhibitors have demonstrated great clinical prospects in early-stage TNBC. To maximize the efficacy of anti-PD-1/PD-L1 therapy, further research into the challenges which still exist is necessary. Full article
(This article belongs to the Special Issue Immunotherapy in Triple Negative Breast Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop